346 related articles for article (PubMed ID: 30339521)
1. Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing.
Ikeda S; Elkin SK; Tomson BN; Carter JL; Kurzrock R
Cancer Biol Ther; 2019; 20(2):219-226. PubMed ID: 30339521
[TBL] [Abstract][Full Text] [Related]
2. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
[TBL] [Abstract][Full Text] [Related]
3. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
[TBL] [Abstract][Full Text] [Related]
4. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
Shaib WL; Zakka K; Staley C; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
Oncologist; 2020 May; 25(5):414-421. PubMed ID: 31784493
[TBL] [Abstract][Full Text] [Related]
5. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.
Park JJ; Chu A; Li J; Ali A; McKay RR; Hwang C; Labriola MK; Jang A; Kilari D; Mo G; Ravindranathan D; Graham LS; Sokolova A; Tripathi A; Pilling A; Jindal T; Ravindra A; Cackowski FC; Sweeney PL; Thapa B; Amery TS; Heath EI; Garje R; Zakharia Y; Koshkin VS; Bilen MA; Schweizer MT; Barata PC; Dorff TB; Cieslik M; Alva AS; Armstrong AJ
JCO Precis Oncol; 2024 Apr; 8():e2300567. PubMed ID: 38579192
[TBL] [Abstract][Full Text] [Related]
6. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.
Schwaederle M; Daniels GA; Piccioni DE; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R
Mol Cancer Ther; 2015 Jun; 14(6):1488-94. PubMed ID: 25852059
[TBL] [Abstract][Full Text] [Related]
7. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
8. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.
Cohen PR; Tomson BN; Elkin SK; Marchlik E; Carter JL; Kurzrock R
Oncotarget; 2016 Apr; 7(17):23454-67. PubMed ID: 26981779
[TBL] [Abstract][Full Text] [Related]
9. Molecular landscape of prostate cancer: implications for current clinical trials.
Khemlina G; Ikeda S; Kurzrock R
Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103
[TBL] [Abstract][Full Text] [Related]
10. Clinical and genomic features of SPOP-mutant prostate cancer.
Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.
Kato S; Okamura R; Baumgartner JM; Patel H; Leichman L; Kelly K; Sicklick JK; Fanta PT; Lippman SM; Kurzrock R
Clin Cancer Res; 2018 Dec; 24(24):6248-6256. PubMed ID: 30348637
[TBL] [Abstract][Full Text] [Related]
13. A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling.
Cheng HH; Klemfuss N; Montgomery B; Higano CS; Schweizer MT; Mostaghel EA; McFerrin LG; Yu EY; Nelson PS; Pritchard CC
Prostate; 2016 Oct; 76(14):1303-11. PubMed ID: 27324988
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
[TBL] [Abstract][Full Text] [Related]
15. Next generation mapping reveals novel large genomic rearrangements in prostate cancer.
Jaratlerdsiri W; Chan EKF; Petersen DC; Yang C; Croucher PI; Bornman MSR; Sheth P; Hayes VM
Oncotarget; 2017 Apr; 8(14):23588-23602. PubMed ID: 28423598
[TBL] [Abstract][Full Text] [Related]
16. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
[TBL] [Abstract][Full Text] [Related]
17. Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.
Stover EH; Oh C; Keskula P; Choudhury AD; Tseng YY; Adalsteinsson VA; Lohr JG; Thorner AR; Ducar M; Kryukov GV; Ha G; Rosenberg M; Freeman SS; Zhang Z; Wu X; Van Allen EM; Takeda DY; Loda M; Wu CL; Taplin ME; Garraway LA; Boehm JS; Huang FW
Prostate; 2022 Apr; 82(5):584-597. PubMed ID: 35084050
[TBL] [Abstract][Full Text] [Related]
18. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
20. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
